This year, Silicon Valley-based biotech company Revance is finishing up clinical trials for a drug called RT002. Like Botox, RT002 is a neuromodulator that reduces lines. The big difference? RT002’s results have been shown to last six months.
“Most other neuromodulators show a clinical duration of three to four months, and the people in this study clearly had improvement for six months on average,” said Dr. Tina Alster, a Washington, D.C., a dermatologic surgeon involved with the clinical trials of RT002.
Will RT002 be less expensive for consumers? Since it isn’t on the market yet, we don’t know, but if Revance sets its price to be competitive with Botox, Dysport, and Xeomin — and fewer treatments are needed — it might be more cost effective.
Dr. Alster said that another benefit of a longer-lasting treatment is convenience. For people who get both toxins and fillers, having a longer-lasting toxin might help them get both treatments on the same schedule.
“Patients don’t just want to have a great clinical result, they want to have that result for as long as possible,” Dr. Alster said. “People have to come in to the office, and it takes a lot of time.
“Well over half of my patients come in for the combination,” she continued. “They come in for Botox, Dysport, or Xeomin, and they get fillers at the same time.”
That’s great news for people who want to minimize office visits. RT002 could also be a great option for people who travel often. “In D.C., I get people who are posted abroad for their work,” she said. “For those people who travel a lot, it makes sense for them to have a longer-lasting neurotoxin.”
Revance plans to release RT002 in 2020, according to this press release, and it’s only being tested for frown lines, aka the 11’s between the eyes. We can’t wait to try it.
Ready to contact an expert? Find a doctor near you.